drugset / Trial / NCT06902844
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed /refractory systemic lupus erythematosus (SLE).
Timeline
- Start
- 2025-04-05
- Primary completion
- 2027-10-31
- Completion
- 2028-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Equecabtagene Autoleucel | Cell therapy | 1e+06 cells/kg | — |